Gluten-free diet improves celiac disease associated with cryptogenic cirrhosis, suggests study
Researchers have discovered that patients who also have biopsy-proven celiac disease (CeD) with cryptogenic cirrhosis benefit significantly by the treatment with a gluten-free diet (GFD). A recent study was conducted by Pachisia and colleagues which was published in The American Journal of Gastroenterology.
Celiac disease frequently involves the liver, and as many as 4.6% of patients with cryptogenic cirrhosis are likely to have undiagnosed CeD. The aim of this study was to determine the prevalence of CeD in patients with cryptogenic cirrhosis and compare liver-related outcomes of these patients after a gluten-free diet (GFD) compared with a propensity-score-matched cohort of patients without CeD on standard care (SOC).
This multicenter study screened 232 consecutive patients with cryptogenic cirrhosis for CeD using IgA anti-tissue transglutaminase antibody (anti-tTG), anti-endomysial antibody (AEA), and duodenal and liver biopsies. Biopsy samples underwent IgA/anti-tTG colocalization studies for definitive diagnosis.
Patients diagnosed with CeD and matched controls without CeD (1:4 ratio, matched by age, sex, Child-Turcotte-Pugh [CTP] score, and MELD score) were treated with GFD plus SOC or SOC alone, respectively. Liver-related outcomes, including MELD and CTP scores, decompensation events, and mortality, were assessed over a one-year follow-up.
Key Findings
Prevalence of CeD in Cryptogenic Cirrhosis :
• Among 232 patients, 14 had elevated anti-tTG antibody levels (16.9±10.5-fold rise), 9 were AEA positive, and 11 (4.7%) were biopsy-proven for CeD.
Baseline Characteristics:
Patients with CeD (n=11) and matched controls (n=44) showed similar baseline demographics and liver disease severity:
• Age: 31.3±7.7 (CeD) vs. 31.8±9.3 years (non-CeD).
• Females: 45.5% (CeD) vs. 34.1% (non-CeD).
• MELD score: Median 9 (IQR: 8–15.5) vs. 12 (9–15).
• CTP score: Median 7 (IQR: 6–7.5) vs. 6 (5.75–7).
Liver Outcomes with GFD:
• Patients with CeD on GFD showed significant improvements in liver scores compared with patients without CeD.
• Follow-up MELD score: Median 9 (IQR: 7.5–10.5) vs. 18.5 (12–20) (p=0.001).
• Follow-up CTP score: Median 5 (IQR: 5–5) vs. 8 (7–9) (p<0.001).
• The number of decompensation events was smaller, and the mortality was not significantly different between CeD patients and non-CeD controls.
• Decompensations: Less frequent in CeD group; no numbers were reported.
• Mortality: 9.1% (CeD) vs. 18.2% (non-CeD) (p=0.67).
Liver-related outcomes improved significantly with GFD among these patients, which signifies the importance of early diagnosis and dietary intervention in this population.
Reference:
Pachisia, A. V., Agarwal, A., Mehta, S., Kumari, A., Dwarakanathan, V., Sharma, S., Kumar, S., Mehra, L., Dutta, R., Das, P., Agrawal, S., Shalimar, Ahuja, V., & Makharia, G. K. (2024). Celiac disease is common in adults with cryptogenic cirrhosis and responds favourably to gluten-free diet. The American Journal of Gastroenterology, 10.14309/ajg.0000000000003244.https://doi.org/10.14309/ajg.0000000000003244
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.